Compare Autozone Inc (AZO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autozone Inc vs Sana Biotechnology Inc — how do they compare? Autozone Inc trades at $3,038.29 (market cap $49.67B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Autozone Inc is far larger — about 44× Sana Biotechnology Inc's market cap, and Autozone Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| AZO | SANA | |
|---|---|---|
Market Cap | $49.67B | $1.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $4.35K | $5.92 |
52-Week Low | $2.92K | $2.68 |
Enterprise Value | $62.05B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AutoZone (AZO) trades at $3,050.43, down 0.57% on the day, with a neutral technical signal and bullish moving averages. The company reported Q1 2026 EPS of $38.07, beating expectations, but revenue growth has slowed with a net income margin of 12.4% in 2025. Analyst consensus is strongly bullish with a $3,730 price target, though recent insider selling and institutional trimming pose sentiment headwinds.
The outlook remains positive given earnings beats and international expansion, but risks include competitive pressures, margin compression, and macroeconomic sensitivity. Upside is supported by a high GF Score of 84 and DCF valuation above $3,800, yet investors should monitor execution on Q2 2026 earnings and capex efficiency.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
